Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Dec;12(6):592-597.
doi: 10.1007/s12328-019-01029-y. Epub 2019 Aug 2.

Successful Prolonged Treatment of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patient With Treatment Failure After 8-week Therapy: A Case Report

Affiliations
Case Reports

Successful Prolonged Treatment of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patient With Treatment Failure After 8-week Therapy: A Case Report

Atsushi Naganuma et al. Clin J Gastroenterol. .

Abstract

Direct-acting antiviral agent (DAA)-based therapies have been the 1st choice of antiviral agents for chronic hepatitis C throughout the world. The treatment period of DAA-based therapy has been greatly shortened by the improvement of their efficiency. Thus, glecaprevir (GLE)/pibrentasvir (PIB) therapy has enabled the therapeutic period to be reduced from 12 to 8 weeks in cases of genotype 1 or 2 chronic hepatitis C without liver cirrhosis. Currently, there is no established rescue therapy for patients who experience treatment failure on GLE/PIB therapy; however, some patients have been rescued by other regimens, including sofosbuvir (SOF)/velpatasvir (VEL) plus ribavirin (RBV) therapy and GLE/PIB, SOF, and RBV therapy. We experienced the case of a DAA-naïve non-cirrhotic patient with genotype 2a who showed virologic relapse at post-treatment week 13 following 8-week GLE/PIB therapy. After we confirmed that he did not have resistance-associated substitutions against GLE or PIB, we tried to rescue the patient using prolonged (12-week) GLE/PIB therapy. Fortunately, a sustained virologic response was achieved without any adverse events. Although this was a single-case report and is assumed to be rare, the same regimen might be effective for treatment failure with 8-week GLE/PIB therapy.

Keywords: Chronic hepatitis C; Direct-acting antiviral agents; Rescue therapy; Treatment failure; Treatment period.

Similar articles

See all similar articles

References

    1. Hepatol Int. 2018 Jul;12(4):356-367 - PubMed
    1. J Gastroenterol. 2018 Apr;53(4):557-565 - PubMed
    1. Hepatol Res. 2019 Jun;49(6):617-626 - PubMed
    1. J Hepatol. 2019 May;70(5):1019-1023 - PubMed
    1. Ann Hepatol. 2018 Apr 9;17(3):525-529 - PubMed

Publication types

LinkOut - more resources

Feedback